Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Lambrinoudaki, Ιrene; Vlachou, Sophia; Galapi, Fotini; Papadimitriou, Dimitra; Papadias, K

doi:10.2147/cia.s2046

Cited by 54 publications

(38 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no need to adjust the dose in patients who have a creatinine clearance of 35 mL/min or higher. Zoledronic acid does not inhibit the P450 enzyme, and there is therefore no interaction with other medications metabolized via cytochrome P450 21. However, caution should be exercised in patients on medications that have the potential of reducing the serum calcium level, such as loop diuretics and aminoglycosides, and potentially nephrotoxic medications, such as nonsteroidal anti-inflammatory compounds.…”

Section: Zoledronic Acidmentioning

confidence: 99%

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

Hamdy¹

2010

DDDT

View full text Add to dashboard Cite

The availability of a once-a-year zoledronic acid infusion heralds a new era in the management of osteoporosis. It virtually eliminates the problem of poor compliance with orally administered bisphosphonates and, because it bypasses the gastrointestinal tract, it is not associated with gastrointestinal side effects. Zoledronic acid is effective for the treatment and prevention of postmenopausal osteoporosis, and for the treatment of osteoporosis in men, and glucocorticoid-induced osteoporosis. When administered within three months of a hip fracture, it reduces mortality and the risk of subsequent fractures. It is remarkably free of serious adverse effects. After administration of the intravenous infusion, about 18% of bisphosphonate-naïve patients experience an acute-phase reaction, including low-grade temperature, aches, and pains. This is reduced to about 9% in those who have been treated with oral bisphosphonates, and is further reduced by the concomitant and subsequent administration of acetaminophen. The likelihood and magnitude of the acute-phase reaction is less after the second infusion. Other adverse effects are similar to those encountered with other bisphosphonates. Because it is mostly excreted by the kidneys, zoledronic acid should not be administered to patients with a creatinine clearance less than 35 mL/min. It should not be administered to patients with hypocalcemia.

show abstract

Section: Zoledronic Acidmentioning

confidence: 99%

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

Hamdy¹

2010

DDDT

View full text Add to dashboard Cite

show abstract

“…Moreover, the study was focused on following the rate of radioactivity clearance from liver and kidney (Figure ). The liver showed low tendency for 99m Tc‐EMIHPBP uptake that reached its maximum value 2.92%ID/gram organ after 120 minutes; this was due to the fact that ZL is not metabolized in liver and is excreted intact in the urine . By following 99m Tc‐EMIHPBP through the kidney, it was suggested that urinary excretion is the main pathway for its removal from the body where about 8.13% ID/gram organ of 99m Tc‐EMIHPBP found in the kidney after 60 minutes was subjected for continuous rapid clearance to reach 16.67% after 360 minutes.…”

Section: Resultsmentioning

confidence: 99%

Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique

Motaleb

Ibrahim

El-Tawoosy

et al. 2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

A novel zoledronic acid (ZL) derivative, 3-(2-ethyl-4-methyi-1H-imidazole-1-yl)-1-hydroxy-1-phosphonopropyl phosphonic acid (EMIHPBP), was synthesized, characterized, and successfully radiolabeled with Tc. The in vivo biodistribution of Tc-EMIHPBP was investigated and compared with the previously reported zoledronate derivatives aiming to formulate a novel zoledronate derivative with a high-potential uptake to bone as a promising antiosteoporotic candidate. To further evaluate the bone uptake efficiency, the pharmacokinetics of Tc-EMIHPBP was investigated and showed that maximum concentration in bone (C ) was 31.60 ± 0.15%ID/gram after 60 minutes (t ). Cumulative residence of Tc-EMIHPBP in the bone [AUC (%ID∙min/gram bone)] was 3685.23, mean residence time was 384.354 minutes, and the calculated bone bioavailability was 15.831%. Finally, the time needed for half of the Tc-EMIHPBP formulation to be eliminated from bone (t ) was 263.914 minutes. Excellent bone uptake can be obtained 1-hour postinjection with high bone/blood ratio of 23.76 detected with gamma counter. The biodistribution and kinetic studies could recommend EMIHPBP as a promising antiosteoporotic candidate with high selectivity to the skeletal system and rapid clearance from soft tissues.

show abstract

“…Usually AEs after using once-yearly ZOL 5 mg were clustered into five groups: acute-phase reactions, such as fever, musculoskeletal, gastrointestinal; hypocalcaemia; renal dysfunction; cardiovascular; eye inflammation; and osteonecrosis of the jaw [40][41][42].…”

Section: Rycina 2 śRednie Liczby Punktów W Poszczególnych Domenach Kmentioning

confidence: 99%

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Huang¹,

Lin²,

Zhu³

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

 Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosisKwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia AbstractIntroduction: Osteoporosis is characterised by decreased bone mass and weakened bones, with an increased risk of fractures. Osteoporotic fracture, the most serious complication of osteoporosis, is related not only to lower bone mineral density (BMD), but also falls. Osteoporosis and fractures are associated with a decreased health-related quality of life (HRQL). Zoledronic acid (ZOL) is an intravenous once-yearly bisphosphonate that has been shown to be effective and safe in improving BMD and reducing fracture risk in controlled clinical trials. Material and methods:In this self-controlled, prospective trial, 220 postmenopausal women with osteoporosis (mean age 67 years) received a single infusion of ZOL 5 mg at baseline and month 12. BMD, HRQL and Fall Index (FI) were measured at baseline, and months 12 and 24 (before each use of ZOL). The main outcome measures were the changes in lumbar spine and hip BMD and the changes in HRQL, the Short Form-36 questionnaire (SF-36). Additional comparisons were based on the FI. LSD multiple comparisons were used in the comparisons of BMD, SF-36 domain scores and FI. Results: The patients had significantly higher L1-4, total hip, femoral neck and trochanter BMD (P < 0.05) with improved HRQL (P < 0.05) over two years of treatment of once-yearly ZOL 5mg. FI was reduced (P < 0.05) with oral daily elemental calcium and vitamin D in the treatment course. Conclusions: ZOL improves BMD and HRQL, especially in the physical aspects, over two years of treatment in women with postmenopausal osteoporosis, and can help improve balance ability. (Endokrynol Pol 2014; 65 (2): 96-104)

show abstract

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Cited by 54 publications

References 39 publications

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Contact Info

Product

Resources

About